Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2027

    Employees

    120

Stocks News & Analysis

stocks

Chip stock selloff deepens in Asia, extends to Europe and US

The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks

Downgrade for ASX listed fund manager as redemptions pile on

Persistent outflows erode earnings outlook.
stocks

Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?

Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.30100.901.14%
CAC 407,934.7061.590.78%
DAX 4025,382.6284.010.33%
Dow JONES (US)52,177.69556.211.08%
FTSE 10010,840.35115.491.08%
HKSE24,317.42254.701.06%
NASDAQ26,713.0320.160.08%
Nikkei 22565,403.46977.511.52%
NZX 50 Index13,745.0487.76-0.63%
S&P 5007,744.0625.120.33%
S&P/ASX 2008,808.3088.601.02%
SSE Composite Index3,742.6635.180.95%

Market Movers